Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 3 days ago

Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial

argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Syst... Full story

Yahoo Finance • 4 days ago

Takeda's Next Wave of Drugs Has Investors Watching Closely

Takeda Pharmaceutical Company Ltd. (NYSE:TAK) reported fourth-quarter sales of $6.98 billion, or 1.094 trillion yen, missing Wall Street estimates of $7.05 billion. The Japanese drugmaker reported adjusted earnings of 28 cents per ADR (89... Full story

Yahoo Finance • 4 days ago

Takeda Pharmaceutical Non-GAAP EPS of ¥517.00, revenue of ¥4505.7B; gives FY2026 forecast

* Takeda Pharmaceutical press release [https://seekingalpha.com/pr/20512619-takeda-announces-fy2025-full-year-results-and-fy2026-outlook-highlighted-by-excellent] (TAK [https://seekingalpha.com/symbol/TAK]): FY Non-GAAP EPS of ¥517.00.... Full story

Yahoo Finance • 6 days ago

Earnings live updates: Plug Power, Hims & Hers set to kick off week of quarterly updates

The pace of first quarter earnings reports eases this week as economic data takes center stage, but investors will still be on the lookout for results from a handful of big corporations. So far this earnings season, S&P 500 companies have... Full story

Yahoo Finance • 11 days ago

Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor

MENLO PARK, Calif., May 06, 2026--(BUSINESS WIRE)--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor. Mr. Walbert brings more than three decades... Full story

Yahoo Finance • 12 days ago

Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality

BOSTON, May 5, 2026 /PRNewswire/ -- Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, Abb... Full story

Yahoo Finance • 12 days ago

Model N Appoints Thomas Gibbs to Board of Directors

Seasoned pharmaceutical executive brings over 25 years of commercial leadership to Model N board REDWOOD CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Model N, a leading end-to-end commercialization, revenue optimization, and compliance... Full story

Yahoo Finance • 13 days ago

Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights

In early May 2026, Takeda informed Denali Therapeutics that it would terminate their collaboration on developing and commercializing DNL593 for business reasons unrelated to the drug’s efficacy or safety, returning full control of the prog... Full story

Yahoo Finance • 15 days ago

Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best Japanese stocks to buy right now. On April 6, Denali Therapeutics said Takeda Pharmaceutical Company Limited (NYSE:TAK) is ending its collaboration on DNL 593.Is Takeda Ph... Full story

Yahoo Finance • 18 days ago

What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in

Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best biotech stocks with highest upside potential. On April 6, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed that it has received notice from Takeda (NYSE: TAK) about the terminati... Full story

Yahoo Finance • 19 days ago

Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma

Company Logo The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs, rare tumors originating... Full story

Yahoo Finance • 20 days ago

Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.

Intellia Therapeutics could soon win Food and Drug Administration approval for the first-ever drug that edits genes inside a patient's body. Continue Reading... Full story

Yahoo Finance • 23 days ago

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics

Company Logo The Germany Anemia Treatment Market is set to reach USD 1.05 billion by 2034, growing at a CAGR of 6.84% from USD 581.344 million in 2025. This growth is driven by an aging population, increased iron-deficiency cases, and the... Full story

Yahoo Finance • 23 days ago

Oncology Clinical Trials Research Report 2026: $20+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The oncology clinical trials market has seen substantial growth, transitioning from $14.9... Full story

Yahoo Finance • last month

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations

Zealand Pharma Eric RojasVP, Head of Investor Relations·GlobeNewswire Inc. Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pha... Full story

Yahoo Finance • last month

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis treatment. Continue Reading... Full story

Yahoo Finance • last month

Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update

WORCESTER, Mass., April 13, 2026 /PRNewswire/ -- Leal Therapeutics, Inc. (Leal), a biotechnology company developing neuro-metabolic therapeutics, today announced the appointments of Johannes Tauscher, M.D., as Chief Medical Officer and Ray... Full story

Yahoo Finance • last month

ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial Officer

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 2, 2026, ABIVAX Société Anonyme (NASDAQ:ABVX) appointed Michael Nesrallah as chief commercial officer. Michael Nesrallah will lead... Full story

Yahoo Finance • last month

Mental Health Market Set to Surpass USD 668.62 Billion by 2035, Owing to the Increased Adoption of Digital Care and AI-Driven Therapies – SNS Insider

Austin, United States, April 03, 2026 (GLOBE NEWSWIRE) -- As per SNS Insider, The global Mental Health Market was estimated at USD 449.96 billion in 2025 and is projected to hit USD 668.62 billion by 2035, recording a CAGR of 4.04% over... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome Therapeutics, Inc. Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a novel mecha... Full story